CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

23 May 2024 14:04:38 By Nasdaq GlobeNewswire

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

15 May 2024 13:05:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

29 Apr 2024 04:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

24 Apr 2024 07:09:18 By Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

16 Apr 2024 04:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

16 Apr 2024 03:59:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14 Mar 2024 04:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

01 Mar 2024 04:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

27 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

18 Dec 2023 13:53:03 By Nasdaq GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

14 Dec 2023 13:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

08 Nov 2023 04:00:03 By Nasdaq GlobeNewswire

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

03 Nov 2023 09:01:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

30 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

06 Sep 2023 05:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

10 Aug 2023 04:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

09 Aug 2023 04:00:51 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

31 Jul 2023 05:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

25 May 2023 14:00:26 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

11 May 2023 13:01:01 By Nasdaq GlobeNewswire